IGF-1 receptor tyrosine kinase inhibitor (Ontogen)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIGF-1 receptor tyrosine kinase inhibitor (Ontogen)
Drug Alias Nameinsulin-like growth factor 1 receptor kinase inhibitors (Ontogen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsPsoriasisProstatic NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOntogen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOntogen
Active IndicationsN/A
Inactive IndicationsPsoriasisProstatic NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A